Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4. As announced on March 3, PharmaTher provided its ...
In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4, 2025. Fabio Chianelli, Chairman and CEO of PharmaThe ...
Kennedy Jr., has pledged to close a legal loophole that has enabled food companies to bypass approval by the Food and Drug Administration (FDA) when introducing new additives into their products.
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The FDA on Friday gave the green light to Mirum’s Ctexli, also known as chenodiol, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). The approval makes chenodiol—already ...
Many of these FDA-approved medical devices can be implanted in a person's body, while others are used outside the body. Health care providers determine which cardiovascular devices, if any ...
They are made by licensed pharmacies, but not approved or inspected by the FDA. Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take ...
Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...
It noted at the time more countries would get access as regulators approved the feature, and the FDA was apparently the first to come through outside of Europe, boosting support to 15 countries.
“We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected ...
Feb. 25, 2025 – The FDA has approved a new treatment plan for a long-acting injection, making it easier for people with moderate to severe opioid use disorder (OUD) to start and keep up with ...
Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient in glucagon-like peptide 1 receptor agonist (GLP-1RA) Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback